Saturday, September 23, 2023
Saturday, September 23, 2023

Triastek Receives FDA IND Clearance for 3D Printed Medicine for the Treatment of Ulcerative Colitis

Triastek, Inc. (“Triastek”) a global healthcare company pioneering 3D printing of pharmaceuticals with its proprietary technology, Melt Extrusion Deposition (MED®), announced today that it has received clearance for its Investigational New Drug (IND) application from the United States Food and Drug Administration (FDA) to initiate clinical studies of the 3D printed medicine, T21, a potential treatment for ulcerative colitis.

“We are excited to receive IND clearance to begin clinical trials of this potentially transformative treatment for patients, ” said Dr. Senping Cheng, founder and CEO of Triastek. “Delaying drug release and delivering oral dosage forms to the colon is challenging, so T21 offers a promising new option for patients by providing site-specific drug delivery and localized drug effect, mitigating potential side effects from systemic exposure. We look forward to advancing this treatment into the clinic and appreciate the FDA’s support. ”

Triastek Receives Fda Ind Clearance For 3D Printed Medicine For The Treatment Of Ulcerative Colitis
Triastek’s Colon-Targeted Drug Delivery Dosage Form Development
Triastek’s Three Products Enter The Clinical Development Phase Within Two Years
Triastek’s Three Products Enter The Clinical Development Phase Within Two Years

T21 is a novel potential treatment capable of colon-targeted drug delivery. With a unique 3D dosage form design, T21 can reach the targeted colon segment of the GI tract, thus permitting use of a lower drug dose than the reference listed drug, which provides systemic exposure. Made possible by 3D printing, radio-imaging agents embedded in specific components of the dosage form were employed in early formulation development to evaluate and confirm the location of drug release in the GI tract. This novel process can be utilized in the development of future drugs targeted to specific segments of the GI tract to increase the efficiency and success rate of product development. The delayed-release, colon-targeted oral tablet technology platform can not only be used for developing small molecule drugs, but for peptide drugs as well.

Triastek had already received IND clearance from the FDA for its T19 and T20 products for treatment of rheumatoid arthritis and cardiovascular and clotting disorders, respectively. Triastek continues to demonstrate the broad applicability of its MED® technology through the advancement of products that solve a wide range of drug delivery challenges across multiple therapeutic areas.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.


FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

FDA OK’s ensoETM for Use in Cardiac Ablations to Reduce Risk of Esophageal Injury

Published studies that have examined the use of ensoETM for this purpose include the pilot eCOOL-AF study, the IMPACT study and a large multi-center analysis of over 25,000 patients (in press at the Journal of the American College of Cardiology: Clinical Electrophysiology). These studies have found up to an 83 percent reduction in esophageal injuries, and a significant reduction in risk of atrioesophageal fistula (AEF), one of the most dreaded complications of ablation procedures. Receives FDA Clearance and Breakthrough Device Designation has also received FDA Breakthrough Device Designation for its obstructive hydrocephalus software tool. This is the first radiology triage device to be granted Breakthrough status since the inception of the FDA Breakthrough Devices Program.

By using this website you agree to accept Medical Device News Magazine Privacy Policy